Parabilis Medicines, Inc. (PBLS) vs Tango Therapeutics, Inc. (TNGX)
A side-by-side comparison of Parabilis Medicines, Inc. and Tango Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PBLS
Parabilis Medicines, Inc.
$28.86HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TNGX
Tango Therapeutics, Inc.
$21.90HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — PBLS vs TNGX
growth of $100 · dividends reinvested · last 1yPBLS +47.7% (+47.7%/yr)TNGX +14.1% (+14.1%/yr)PBLS compounded faster over this window
PBLS TNGX
PBLS vs TNGX: by the numbers
- •TNGX is the larger company ($3.57B vs $3.36B market cap).
- •Both run net losses; PBLS's is the smaller (0.00% vs -229.92% net margin).
Metrics side by side
Valuation
| Metric | PBLS | TNGX |
|---|---|---|
| P/S ratio | N/A | 66.26 |
| P/B ratio | 3.21 | 3.48 |
Profitability
| Metric | PBLS | TNGX |
|---|---|---|
| Gross margin | 0.00% | 98.25% |
| Operating margin | 0.00% | -178.39% |
| Net margin | 0.00% | -229.92% |
| ROE | N/A | -12.08% |
| ROIC | -409.85% | -12.91% |
Growth (annualized)
| Metric | PBLS | TNGX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 19.14% |
| Total return CAGR (5Y) | N/A | 10.60% |
Go deeper
Dig into the metrics
Parabilis Medicines ROETango Therapeutics ROEParabilis Medicines operating marginTango Therapeutics operating marginParabilis Medicines revenue growthTango Therapeutics revenue growthParabilis Medicines free cash flowTango Therapeutics free cash flow
Parabilis Medicines & Tango Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.